Next-Generation Sequencing For Drug Designing And Development: An Omics Approach For Cancer Treatment

Next Generation Sequencing (NGS) techniques retain the potential to open up avenue to identify novel therapeutic target guided drug to pursue and proving as an efficient alternative technology for denovo drug design. Its remarkable applications are established in relation to therapeutic diagnosis and treatment of multifactorial diseases including cancer. The NGS accurately predicts cellular reactions at genomic, transcriptomic or proteomic level. Its impact in novel anticancer drug designing relies on its therapeutic approaches, multiplexing of samples and high diagnostic sensitivity for genetic and epigenetic biomarkers. Development of new therapies and drug usually takes longer time and require recruiting considerable pools of patient. NGS cut down cost of drug development and time by using its unseen potential to identified specific therapeutic target and new pathophysiological pathways involvement in cancer, helped in designing of targeted drug and correct evaluation of its deleterious side effect. Furthermore, improved gene and disease interaction validations techniques changed entire cancer therapy methods. This is a critical review of multiple approaches of NGS in development of anti-cancer drug including biomarkers based diagnosis and recent trends of targeted capture technology based personalised medicine in cancer therapy. Additionally, emerging paradigm in disease diagnosis based on state-of-art third generation sequencing technologies have also discussed.